These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2462881)

  • 1. Iloprost binding and inhibition of aggregation in platelet rich plasma. Differences between normal and type IIa hypercholesterolemic subjects.
    Oliva DW; Maderna P; Accomazzo MR; Nicosia S; Tremoli E
    Biochem Pharmacol; 1989 Jan; 38(1):39-45. PubMed ID: 2462881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
    Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A
    Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin reduces platelet thromboxane formation and restores normal platelet sensitivity against prostacyclin in type IIa hypercholesterolemia.
    Schrör K; Löbel P; Steinhagen-Thiessen E
    Eicosanoids; 1989; 2(1):39-45. PubMed ID: 2483819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The single prostacyclin receptor of gel-filtered platelets provides a correlation with antiaggregatory potency of PGI2 mimics.
    Eggerman TL; Hartzell CJ; Selfe S; Andersen NH
    Thromb Res; 1987 Mar; 45(5):645-59. PubMed ID: 3296302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of equimolar concentrations of iloprost, prostacyclin, and prostaglandin E1 on human platelet function.
    Fisher CA; Kappa JR; Sinha AK; Cottrell ED; Reiser HJ; Addonizio VP
    J Lab Clin Med; 1987 Feb; 109(2):184-90. PubMed ID: 2433373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of inhibitory actions of prostacyclin and a new prostacyclin analogue on the aggregation of human platelet in whole blood.
    Saniabadi AR; Belch JJ; Lowe GD; Barbenel JC; Forbes CD
    Haemostasis; 1987; 17(3):147-53. PubMed ID: 2440771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of anti-aggregatory effects of PGI2, PGI3 and iloprost on human and rabbit platelets.
    Kobzar G; Mardla V; Järving I; Samel N
    Cell Physiol Biochem; 2001; 11(5):279-84. PubMed ID: 11684817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of heparin on prostacyclin binding and platelet adenylate cyclase activity stimulated by iloprost and forskolin.
    Jaschonek K; Faul C; Daiss W; Weisenberger H
    Prostaglandins Leukot Med; 1986 Oct; 24(2-3):199-206. PubMed ID: 2432618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Critical evaluation of the in vivo selectivity between hypotensive and platelet antiaggregating actions of iloprost and prostacyclin in beagle dogs.
    Hermán F; Hadházy P; Magyar K
    Arch Int Pharmacodyn Ther; 1989; 300():281-91. PubMed ID: 2482710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute reversible reduction of PGI2 platelet receptors after iloprost infusion in man.
    Modesti PA; Fortini A; Poggesi L; Boddi M; Abbate R; Gensini GF
    Thromb Res; 1987 Dec; 48(6):663-9. PubMed ID: 2448896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIa hypercholesterolemia.
    Colli S; Lombroso M; Maderna P; Tremoli E; Nicosia S
    Biochem Pharmacol; 1983 Jul; 32(13):1989-93. PubMed ID: 6347202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential inhibition of the platelet activation sequence: shape change, micro- and macro-aggregation, by a stable prostacyclin analogue (Iloprost).
    Pedvis LG; Wong T; Frojmovic MM
    Thromb Haemost; 1988 Apr; 59(2):323-8. PubMed ID: 2455359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin endoperoxide analogues which are both thromboxane receptor antagonists and prostacyclin mimetics.
    Armstrong RA; Jones RL; MacDermot J; Wilson NH
    Br J Pharmacol; 1986 Mar; 87(3):543-51. PubMed ID: 3026540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stabilization of standard platelet concentrates and minimization of the platelet storage lesion by a prostacyclin analogue.
    Elias M; Heethuis A; Weggemans M; Bom V; Blom N; McShine RL; Halie MR; Smit Sibinga CT
    Ann Hematol; 1992 Jun; 64(6):292-8. PubMed ID: 1379080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cholestyramine treatment of type IIa hypercholesterolaemia normalizes platelet reactivity against prostacyclin.
    Löbel P; Steinhagen-Thiessen E; Schrör K
    Eur J Clin Invest; 1988 Jun; 18(3):256-60. PubMed ID: 2458263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet sensitivity in vitro to the prostacyclin analogue iloprost in diabetic patients.
    Vicari AM; Macagni A; Pozza G
    Horm Metab Res; 1989 Nov; 21(11):616-8. PubMed ID: 2480323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA; Jones RL; Peesapati V; Will SG; Wilson NH
    Br J Pharmacol; 1985 Mar; 84(3):595-607. PubMed ID: 2580580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet prostacyclin binding in smokers.
    Jaschonek K; Weisenberger H; Tidow S; Daiss W; Renn W; Ostendorf P
    J Lab Clin Med; 1986 Aug; 108(2):88-95. PubMed ID: 3016128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral naftidrofuryl prevents platelet hyperreactivity ex vivo and inhibits functional desensitization to prostacyclin in hypercholesterolemic rabbits.
    Weber AA; Hohlfeld T; Strobach H; Schrör K
    J Cardiovasc Pharmacol; 1993 Feb; 21(2):332-8. PubMed ID: 7679170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.